Veterinary Biologics Market

By Product;

Vaccines- (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines) Bacterial Extracts ,Monoclonal Antibody, Immunomodulatory-(Cytokines and Others), and Allergenic Extracts

By Animal Type;

Companion Animals, Canine, Avian, Feline, Livestock, and Equine

By Distribution Channel;

Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Retail Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn156116658 Published Date: June, 2025 Updated Date: August, 2025

Veterinary Biologics Market Overview

Veterinary Biologics Market (USD Million)

Veterinary Biologics Market was valued at USD 26,621.32 million in the year 2024. The size of this market is expected to increase to USD 40,028.63 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.


Veterinary Biologics Market

*Market size in USD million

CAGR 6.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.0 %
Market Size (2024)USD 26,621.32 Million
Market Size (2031)USD 40,028.63 Million
Market ConcentrationMedium
Report Pages381
26,621.32
2024
40,028.63
2031

Major Players

  • Elanco Animal Health
  • Ceva
  • Phibro Animal Health Corporation
  • Boehringer Ingelheim
  • Zoetis, Inc.
  • Merck Animal Health
  • Virbac
  • Hester Biosciences Limited

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Veterinary Biologics Market

Fragmented - Highly competitive market without dominant players


The Veterinary Biologics Market is advancing robustly as animal health professionals adopt biologically derived vaccines, diagnostics, and biosimilars to improve disease prevention and treatment. With nearly 60% of large and small animal producers now using biologics, growth is accelerating, driven by rising demand for safer, targeted solutions. This opens up significant opportunities for biologics manufacturers to innovate in formulation and delivery, supporting broad expansion in pet and livestock healthcare.

Collaborative R&D Accelerating Product Pipelines
The market is strengthened by increased collaboration among biotech firms, veterinary universities, and government research stations. Over 55% of new biologic candidates arise from partnerships focusing on zoonotic disease control, orphan animal diseases, and region‑specific pathogens. Strategic merger activity also boosts manufacturing scale, regulatory expertise, and access to global distribution networks—supporting continued growth.

Strategic Rollout Enhancing Market Penetration
Manufacturers are executing effective strategies such as bundled health kits, farm‑level vaccination programs, veterinary education initiatives, and support packages for regulatory submissions. As a result, approximately 70% of dairy farms and 65% of companion‑animal clinics now deploy branded biologics. These programs reinforce clinician trust and drive widespread expansion across animal care settings.

Smart Biologics Shaping Future Animal Health
The future outlook focuses on innovation in smart biologics—such as thermostable vaccines, nanoparticle‑based delivery systems, and diagnostic‑embedded immunizations. More than 75% of current R&D efforts target these enhancements to simplify cold‑chain logistics and enable point‑of‑care administration. These technological advancements are poised to sustain long‑term growth and expand the footprint of biologics in veterinary healthcare.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Animal Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Veterinary Biologics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Pet Adoption
        2. Increase in Zoonotic Diseases
        3. Demand for Food Safety
        4. Advancements in Biotechnology
      2. Restraints
        1. Regulatory Hurdles
        2. High Development Costs
        3. Limited Awareness
        4. Storage and Distribution Challenges
      3. Opportunities
        1. Emerging Markets Expansion
        2. Customized Vaccines
        3. Biotechnology Innovations
        4. One Health Approach
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Veterinary Biologics Market, By Product, 2021 - 2031 (USD Million)
      1. Vaccines
        1. Attenuated Live Vaccines
        2. Conjugate Vaccines
        3. Inactivated Vaccines
        4. Subunit Vaccines
        5. Toxoid Vaccines
        6. DNA Vaccines
        7. Recombinant Vaccines
      2. Bacterial Extracts
      3. Monoclonal Antibody
      4. Immunomodulatory
        1. Cytokines
        2. Others
      5. Allergenic Extracts
    2. Veterinary Biologics Market, By Animal Type, 2021 - 2031 (USD Million)
      1. Companion Animals
      2. Canine
      3. Avian
      4. Feline
      5. Livestock
      6. Equine
    3. Veterinary Biologics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Veterinary Clinics
      2. Veterinary Hospitals
      3. Veterinary Research Institutes
      4. Retail Pharmacies
    4. Veterinary Biologics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Elanco Animal Health
      2. Ceva
      3. Phibro Animal Health Corporation
      4. Boehringer Ingelheim
      5. Zoetis, Inc.
      6. Merck Animal Health
      7. Virbac
      8. Hester Biosciences Limited
  7. Analyst Views
  8. Future Outlook of the Market